JAMA · 1980 · 19 citations · 15 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyHemodynamic ManagementRenal PharmacotherapyBlood Pressure ManagementDiuretic TherapyHypertension ManagementHypertension PharmacotherapyAldosterone PhysiologyBlood PressureCaptopril TherapyHypertensive Drug ResponseMaintenance Requirements AnalysisPlasma Renin ActivityRenal Function EvaluationRenin-angiotensin-aldosterone System Activation
Eight hypertensive patients with normal renal function and receiving diuretic therapy for at least 28 days received captopril in small increasing doses (6.25, 12.5, and 25 mg). Supine and standing blood pressure (BP) and pulse rate, plasma renin activity (PRA), and plasma aldosterone concentration (PAC) were measured before and after captopril administration. The mean (+/- SEM) maximal decline in BP was 38/18 +/- 3/2, 34/18 +/- 4/2, and 25/17 +/- 3/2 mm Hg and occurred within 70 minutes of each of the three doses. In contrast, the duration of a 10 mm Hg or greater decrease in BP was prolonged markedly (103 +/- 5, 175 +/- 15, and 287 +/- 10 minutes) after each dose increment. After captopril, mean PRA levels increased while PAC levels fell. Transient dizziness on standing occurred in two patients, but captopril was otherwise well tolerated. Evaluation of the response to initial doses of captopril appears to be helpful in predicting maintenance requirements.
15
David B. Case, Steven A. Atlas, John H. Laragh et al. · Progress in Cardiovascular Diseases · 1978 · 366 citations
Medicine, Cardiology, Pharmacology +16
A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MAN
RogerK. Ferguson, Hans-R. Brunner, GustaveA. Turini et al. · The Lancet · 1977 · 325 citations